Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteremia | 13 | 2024 | 79 | 4.180 |
Why?
|
| Staphylococcal Infections | 10 | 2021 | 31 | 4.150 |
Why?
|
| Anti-Bacterial Agents | 27 | 2024 | 293 | 3.700 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 8 | 2021 | 12 | 3.280 |
Why?
|
| beta-Lactamases | 12 | 2024 | 23 | 2.530 |
Why?
|
| Drug Resistance, Bacterial | 15 | 2024 | 135 | 2.490 |
Why?
|
| Bacterial Proteins | 8 | 2023 | 119 | 2.190 |
Why?
|
| Microbial Sensitivity Tests | 22 | 2024 | 198 | 2.160 |
Why?
|
| Enterobacteriaceae Infections | 5 | 2024 | 10 | 2.030 |
Why?
|
| Cross Infection | 11 | 2021 | 52 | 1.930 |
Why?
|
| Carbapenems | 5 | 2024 | 17 | 1.720 |
Why?
|
| South Africa | 42 | 2024 | 7596 | 1.320 |
Why?
|
| Enterobacteriaceae | 3 | 2024 | 11 | 1.260 |
Why?
|
| Humans | 54 | 2024 | 14537 | 1.260 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2022 | 7 | 1.250 |
Why?
|
| Klebsiella pneumoniae | 7 | 2023 | 39 | 1.120 |
Why?
|
| Staphylococcus aureus | 4 | 2020 | 43 | 1.110 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2024 | 6 | 1.100 |
Why?
|
| Communicable Diseases | 4 | 2022 | 62 | 1.080 |
Why?
|
| Acinetobacter Infections | 2 | 2024 | 4 | 1.020 |
Why?
|
| Blood Culture | 3 | 2020 | 11 | 0.990 |
Why?
|
| Population Surveillance | 6 | 2020 | 325 | 0.960 |
Why?
|
| Pseudomonas Infections | 3 | 2022 | 3 | 0.950 |
Why?
|
| Acinetobacter baumannii | 2 | 2022 | 11 | 0.940 |
Why?
|
| Methicillin Resistance | 3 | 2020 | 3 | 0.930 |
Why?
|
| Genomics | 2 | 2024 | 109 | 0.910 |
Why?
|
| Community-Acquired Infections | 3 | 2017 | 102 | 0.900 |
Why?
|
| Exotoxins | 2 | 2020 | 2 | 0.830 |
Why?
|
| Leukocidins | 2 | 2020 | 2 | 0.830 |
Why?
|
| Bacterial Toxins | 2 | 2020 | 3 | 0.830 |
Why?
|
| Urinary Tract Infections | 2 | 2013 | 12 | 0.820 |
Why?
|
| Tertiary Care Centers | 2 | 2022 | 80 | 0.820 |
Why?
|
| Disease Outbreaks | 9 | 2023 | 111 | 0.780 |
Why?
|
| Anti-Infective Agents | 4 | 2021 | 57 | 0.780 |
Why?
|
| Infant | 12 | 2024 | 2244 | 0.750 |
Why?
|
| Adult | 23 | 2024 | 5913 | 0.750 |
Why?
|
| Laboratories | 2 | 2020 | 47 | 0.740 |
Why?
|
| Male | 20 | 2024 | 6754 | 0.730 |
Why?
|
| Middle Aged | 16 | 2024 | 3601 | 0.730 |
Why?
|
| Child | 13 | 2024 | 2242 | 0.710 |
Why?
|
| Staphylococcal Protein A | 1 | 2020 | 1 | 0.700 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2020 | 2 | 0.700 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2020 | 7 | 0.700 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 1 | 0.690 |
Why?
|
| Abscess | 1 | 2020 | 3 | 0.690 |
Why?
|
| Skin Diseases | 1 | 2020 | 6 | 0.690 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 132 | 0.690 |
Why?
|
| Female | 23 | 2024 | 9103 | 0.680 |
Why?
|
| Chromosomes, Bacterial | 1 | 2019 | 1 | 0.660 |
Why?
|
| Genetic Variation | 2 | 2020 | 175 | 0.650 |
Why?
|
| Child, Preschool | 10 | 2024 | 1748 | 0.640 |
Why?
|
| Private Sector | 1 | 2019 | 45 | 0.630 |
Why?
|
| Colistin | 3 | 2024 | 5 | 0.620 |
Why?
|
| Public Sector | 1 | 2019 | 82 | 0.610 |
Why?
|
| Sepsis | 4 | 2023 | 102 | 0.600 |
Why?
|
| Young Adult | 9 | 2024 | 2498 | 0.570 |
Why?
|
| Adolescent | 12 | 2024 | 2985 | 0.550 |
Why?
|
| Infant, Newborn | 13 | 2024 | 1479 | 0.530 |
Why?
|
| Molecular Epidemiology | 4 | 2021 | 47 | 0.490 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2022 | 37 | 0.460 |
Why?
|
| Aged | 8 | 2018 | 1740 | 0.460 |
Why?
|
| Risk Factors | 9 | 2024 | 1475 | 0.440 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 1422 | 0.430 |
Why?
|
| Antimicrobial Stewardship | 4 | 2020 | 14 | 0.410 |
Why?
|
| Retrospective Studies | 5 | 2020 | 799 | 0.410 |
Why?
|
| Meningitis | 2 | 2022 | 26 | 0.380 |
Why?
|
| Klebsiella Infections | 2 | 2023 | 13 | 0.380 |
Why?
|
| Prevalence | 4 | 2024 | 1192 | 0.370 |
Why?
|
| Methicillin | 2 | 2020 | 2 | 0.350 |
Why?
|
| Bacterial Infections | 3 | 2024 | 54 | 0.340 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 468 | 0.320 |
Why?
|
| Drug Resistance, Microbial | 4 | 2020 | 26 | 0.320 |
Why?
|
| Multilocus Sequence Typing | 2 | 2020 | 19 | 0.310 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 90 | 0.300 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 30 | 0.290 |
Why?
|
| Acinetobacter | 1 | 2024 | 1 | 0.230 |
Why?
|
| Africa | 2 | 2024 | 376 | 0.230 |
Why?
|
| Bacteria | 1 | 2024 | 47 | 0.220 |
Why?
|
| Botulism | 1 | 2004 | 1 | 0.220 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2021 | 10 | 0.220 |
Why?
|
| Genotype | 3 | 2021 | 442 | 0.220 |
Why?
|
| Carrier State | 1 | 2024 | 92 | 0.210 |
Why?
|
| Enterococcus faecium | 2 | 2019 | 3 | 0.210 |
Why?
|
| Sentinel Surveillance | 2 | 2014 | 115 | 0.190 |
Why?
|
| Perinatal Death | 1 | 2022 | 33 | 0.190 |
Why?
|
| DNA, Bacterial | 2 | 2020 | 53 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 43 | 0.180 |
Why?
|
| Pandemics | 2 | 2021 | 296 | 0.180 |
Why?
|
| Bronchial Fistula | 1 | 2001 | 1 | 0.180 |
Why?
|
| Esophageal Fistula | 1 | 2001 | 1 | 0.180 |
Why?
|
| Esophageal Diseases | 1 | 2001 | 3 | 0.180 |
Why?
|
| Ulcer | 1 | 2001 | 7 | 0.180 |
Why?
|
| Vancomycin | 1 | 2020 | 6 | 0.180 |
Why?
|
| Miners | 1 | 2020 | 7 | 0.170 |
Why?
|
| Hospital Units | 1 | 2020 | 7 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 2 | 2022 | 15 | 0.170 |
Why?
|
| Advisory Committees | 1 | 2020 | 14 | 0.170 |
Why?
|
| Gold | 1 | 2020 | 38 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 17 | 0.170 |
Why?
|
| Coronavirus | 1 | 2020 | 14 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2017 | 133 | 0.160 |
Why?
|
| Enterobacter | 1 | 2019 | 2 | 0.160 |
Why?
|
| Bacterial Typing Techniques | 1 | 2019 | 11 | 0.160 |
Why?
|
| Neonatal Sepsis | 1 | 2020 | 29 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2019 | 30 | 0.160 |
Why?
|
| Malaria, Falciparum | 1 | 2000 | 39 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 45 | 0.160 |
Why?
|
| Capacity Building | 1 | 2020 | 32 | 0.160 |
Why?
|
| Virulence Factors | 1 | 2019 | 18 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 2 | 2021 | 260 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2001 | 187 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 529 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Communicable Disease Control | 2 | 2011 | 101 | 0.150 |
Why?
|
| Drug and Narcotic Control | 1 | 2017 | 2 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 63 | 0.140 |
Why?
|
| Streptococcus agalactiae | 1 | 1999 | 202 | 0.140 |
Why?
|
| Developing Countries | 1 | 2020 | 400 | 0.140 |
Why?
|
| Streptococcal Infections | 1 | 1999 | 184 | 0.130 |
Why?
|
| beta-Lactams | 1 | 2016 | 7 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 18 | 0.130 |
Why?
|
| Infection Control | 3 | 2020 | 31 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Hospitalization | 2 | 2015 | 418 | 0.120 |
Why?
|
| Age Distribution | 1 | 2015 | 107 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 45 | 0.120 |
Why?
|
| Hospitals | 3 | 2024 | 103 | 0.120 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 2 | 2010 | 336 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2016 | 240 | 0.110 |
Why?
|
| Hospitals, University | 2 | 2006 | 16 | 0.110 |
Why?
|
| India | 1 | 2013 | 62 | 0.100 |
Why?
|
| Urinalysis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 266 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2024 | 1160 | 0.090 |
Why?
|
| Bacteria, Anaerobic | 1 | 2011 | 3 | 0.090 |
Why?
|
| HIV Infections | 6 | 2014 | 5097 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 29 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 124 | 0.090 |
Why?
|
| Incidence | 3 | 2020 | 685 | 0.090 |
Why?
|
| Health Promotion | 1 | 2011 | 109 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 20 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2024 | 95 | 0.080 |
Why?
|
| Salmonella Infections | 1 | 2009 | 3 | 0.080 |
Why?
|
| Salmonella typhimurium | 1 | 2009 | 4 | 0.080 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2010 | 100 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2010 | 303 | 0.080 |
Why?
|
| Health Surveys | 1 | 2008 | 59 | 0.070 |
Why?
|
| Animals | 2 | 2017 | 1081 | 0.070 |
Why?
|
| HIV Antibodies | 1 | 2010 | 247 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 329 | 0.070 |
Why?
|
| Prognosis | 1 | 2008 | 199 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 195 | 0.070 |
Why?
|
| Pregnancy | 2 | 2024 | 1862 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 48 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2011 | 543 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2008 | 889 | 0.060 |
Why?
|
| Calcitonin | 1 | 2004 | 10 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2004 | 22 | 0.060 |
Why?
|
| Food Preservation | 1 | 2004 | 2 | 0.060 |
Why?
|
| Fishes | 1 | 2004 | 3 | 0.060 |
Why?
|
| Food Microbiology | 1 | 2004 | 4 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 21 | 0.060 |
Why?
|
| Ethiopia | 1 | 2024 | 18 | 0.060 |
Why?
|
| Feces | 1 | 2024 | 30 | 0.060 |
Why?
|
| Biological Assay | 1 | 2004 | 32 | 0.050 |
Why?
|
| Rectum | 1 | 2024 | 22 | 0.050 |
Why?
|
| Mice | 1 | 2004 | 135 | 0.050 |
Why?
|
| Vagina | 1 | 2024 | 91 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2001 | 253 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2022 | 9 | 0.050 |
Why?
|
| Oxacillin | 1 | 2022 | 1 | 0.050 |
Why?
|
| Disk Diffusion Antimicrobial Tests | 1 | 2022 | 3 | 0.050 |
Why?
|
| Imipenem | 1 | 2022 | 6 | 0.050 |
Why?
|
| HIV-1 | 1 | 2010 | 1260 | 0.050 |
Why?
|
| O Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Flagellin | 1 | 2022 | 3 | 0.050 |
Why?
|
| Serotyping | 1 | 2022 | 66 | 0.050 |
Why?
|
| HIV | 1 | 2004 | 380 | 0.050 |
Why?
|
| Pediatrics | 1 | 2021 | 17 | 0.040 |
Why?
|
| Serogroup | 1 | 2022 | 150 | 0.040 |
Why?
|
| Diarrhea, Infantile | 1 | 2000 | 2 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 2004 | 299 | 0.040 |
Why?
|
| Crowding | 1 | 2020 | 3 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 2 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2020 | 3 | 0.040 |
Why?
|
| China | 1 | 2020 | 21 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2000 | 1 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2000 | 3 | 0.040 |
Why?
|
| Patient Admission | 1 | 2000 | 11 | 0.040 |
Why?
|
| Biomarkers | 2 | 2016 | 327 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 198 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Diarrhea | 1 | 2000 | 76 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2001 | 370 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 563 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 1999 | 26 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2017 | 111 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 96 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2016 | 55 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 106 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 21 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 66 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2017 | 322 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 480 | 0.030 |
Why?
|
| Plague | 1 | 2012 | 1 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 30 | 0.020 |
Why?
|
| Quality Control | 1 | 2012 | 27 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 18 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 2012 | 38 | 0.020 |
Why?
|
| Health Services | 1 | 2012 | 51 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 179 | 0.020 |
Why?
|
| National Health Programs | 1 | 2011 | 78 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 77 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 150 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2009 | 32 | 0.020 |
Why?
|
| Malaria | 1 | 2012 | 213 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 324 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 158 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2004 | 8 | 0.010 |
Why?
|
| Platelet Count | 1 | 2004 | 14 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 51 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 80 | 0.010 |
Why?
|
| Birth Weight | 1 | 2004 | 80 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 188 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 133 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 171 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 254 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 227 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 370 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2004 | 265 | 0.010 |
Why?
|
| Length of Stay | 1 | 2000 | 43 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2000 | 52 | 0.010 |
Why?
|
| Risk Management | 1 | 2000 | 4 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2000 | 22 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2000 | 76 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2000 | 120 | 0.010 |
Why?
|
| Neoplasms | 1 | 2000 | 147 | 0.010 |
Why?
|